264 related articles for article (PubMed ID: 16601698)
1. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome.
Jokiranta TS; Jaakola VP; Lehtinen MJ; Pärepalo M; Meri S; Goldman A
EMBO J; 2006 Apr; 25(8):1784-94. PubMed ID: 16601698
[TBL] [Abstract][Full Text] [Related]
2. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d.
Bhattacharjee A; Lehtinen MJ; Kajander T; Goldman A; Jokiranta TS
Mol Immunol; 2010 May; 47(9):1686-91. PubMed ID: 20378178
[TBL] [Abstract][Full Text] [Related]
3. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
[TBL] [Abstract][Full Text] [Related]
4. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
Hyvärinen S; Meri S; Jokiranta TS
Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
[TBL] [Abstract][Full Text] [Related]
5. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
[TBL] [Abstract][Full Text] [Related]
6. Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H.
Morgan HP; Jiang J; Herbert AP; Kavanagh D; Uhrin D; Barlow PN; Hannan JP
Acta Crystallogr D Biol Crystallogr; 2011 Jul; 67(Pt 7):593-600. PubMed ID: 21697597
[TBL] [Abstract][Full Text] [Related]
7. Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site.
Perkins SJ; Goodship TH
J Mol Biol; 2002 Feb; 316(2):217-24. PubMed ID: 11851332
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional characterization of the product of disease-related factor H gene conversion.
Herbert AP; Kavanagh D; Johansson C; Morgan HP; Blaum BS; Hannan JP; Barlow PN; Uhrín D
Biochemistry; 2012 Mar; 51(9):1874-84. PubMed ID: 22320225
[TBL] [Abstract][Full Text] [Related]
9. Recognition of malondialdehyde-modified proteins by the C terminus of complement factor H is mediated via the polyanion binding site and impaired by mutations found in atypical hemolytic uremic syndrome.
Hyvärinen S; Uchida K; Varjosalo M; Jokela R; Jokiranta TS
J Biol Chem; 2014 Feb; 289(7):4295-306. PubMed ID: 24344133
[TBL] [Abstract][Full Text] [Related]
10. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions.
Józsi M; Heinen S; Hartmann A; Ostrowicz CW; Hälbich S; Richter H; Kunert A; Licht C; Saunders RE; Perkins SJ; Zipfel PF; Skerka C
J Am Soc Nephrol; 2006 Jan; 17(1):170-7. PubMed ID: 16338962
[TBL] [Abstract][Full Text] [Related]
11. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement.
Kajander T; Lehtinen MJ; Hyvärinen S; Bhattacharjee A; Leung E; Isenman DE; Meri S; Goldman A; Jokiranta TS
Proc Natl Acad Sci U S A; 2011 Feb; 108(7):2897-902. PubMed ID: 21285368
[TBL] [Abstract][Full Text] [Related]
12. Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro.
Loeven MA; Rops AL; Lehtinen MJ; van Kuppevelt TH; Daha MR; Smith RJ; Bakker M; Berden JH; Rabelink TJ; Jokiranta TS; van der Vlag J
J Biol Chem; 2016 Mar; 291(10):4974-81. PubMed ID: 26728463
[TBL] [Abstract][Full Text] [Related]
13. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.
Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S
J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127
[TBL] [Abstract][Full Text] [Related]
14. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site.
Jokiranta TS; Cheng ZZ; Seeberger H; Jòzsi M; Heinen S; Noris M; Remuzzi G; Ormsby R; Gordon DL; Meri S; Hellwage J; Zipfel PF
Am J Pathol; 2005 Oct; 167(4):1173-81. PubMed ID: 16192651
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.
Sánchez-Corral P; Pérez-Caballero D; Huarte O; Simckes AM; Goicoechea E; López-Trascasa M; de Córdoba SR
Am J Hum Genet; 2002 Dec; 71(6):1285-95. PubMed ID: 12424708
[TBL] [Abstract][Full Text] [Related]
16. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
[TBL] [Abstract][Full Text] [Related]
17. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H.
Cheng ZZ; Hellwage J; Seeberger H; Zipfel PF; Meri S; Jokiranta TS
Mol Immunol; 2006 Mar; 43(7):972-9. PubMed ID: 16023208
[TBL] [Abstract][Full Text] [Related]
18. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
[TBL] [Abstract][Full Text] [Related]
19. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.
Manuelian T; Hellwage J; Meri S; Caprioli J; Noris M; Heinen S; Jozsi M; Neumann HP; Remuzzi G; Zipfel PF
J Clin Invest; 2003 Apr; 111(8):1181-90. PubMed ID: 12697737
[TBL] [Abstract][Full Text] [Related]
20. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.
Bhattacharjee A; Reuter S; Trojnár E; Kolodziejczyk R; Seeberger H; Hyvärinen S; Uzonyi B; Szilágyi Á; Prohászka Z; Goldman A; Józsi M; Jokiranta TS
J Biol Chem; 2015 Apr; 290(15):9500-10. PubMed ID: 25659429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
